SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-015267
Filing Date
2023-05-03
Accepted
2023-05-03 16:55:25
Documents
77
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20230331.htm   iXBRL 10-Q 1028701
2 EX-10.1 vnda3312023ex101.htm EX-10.1 30504
3 EX-10.2 vnda3312023ex102.htm EX-10.2 29771
4 EX-31.1 vndaex311331202310q.htm EX-31.1 10579
5 EX-31.2 vndaex312331202310q.htm EX-31.2 10203
6 EX-32.1 vndaex321331202310q.htm EX-32.1 6762
  Complete submission text file 0001628280-23-015267.txt   5492311

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20230331.xsd EX-101.SCH 45520
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20230331_cal.xml EX-101.CAL 63411
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20230331_def.xml EX-101.DEF 191681
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20230331_lab.xml EX-101.LAB 506146
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20230331_pre.xml EX-101.PRE 343236
71 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20230331_htm.xml XML 778589
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 23885083
SIC: 2834 Pharmaceutical Preparations